Angela Brodie

USPTO Granted Patents = 12 (Patent Applications = 10)

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 2.3

ph-index = 7

Forward Citations = 143(Granted Patents)

Company Filing History:

11 out of 1,934

University System of Maryland

patents

1 out of 366

Research Corporation Technologies, Inc.

patents

Years Active: 1993-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10098896 - C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity (2018-10-16),

2. 9295679 - Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity (2016-03-29),

3. 9018198 - Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity (2015-04-28),

4. 8785423 - Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases (2014-07-22),

5. 8110550 - HDAC inhibitors and hormone targeted drugs for the treatment of cancer (2012-02-07),

6. 7875599 - C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity (2011-01-25),

7. 6444683 - 17-azolyl steroids useful as androgen synthesis inhibitors (2002-09-03),

8. 6200965 - 17-Azolyl steroids useful as androgren synthesis inhibitors (2001-03-13),

9. 6133280 - Androgen synthesis inhibitors (2000-10-17),

10. 5994335 - 17-azolyl steroids useful as androgen synthesis inhibitors (1999-11-30),

11. 5994334 - Androgen synthesis inhibitors (1999-11-30),

12. 5264427 - 20-substituted pregnene derivatives and their use as androgen synthesis (1993-11-23),

Title: The Legacy of Angela Brodie: Pioneering Cancer Researcher

Introduction: Angela Brodie, a renowned inventor hailing from Fulton, MD, made significant contributions to the field of cancer research, particularly in the development of treatments for hormone-related cancers.

Latest Patents: Angela Brodie held several patents related to novel cancer therapies targeting hormone receptors, including a groundbreaking method for inhibiting the growth of hormone-dependent tumors.

Career Highlights: Brodie's illustrious career spanned several decades, during which she conducted groundbreaking research at the University of Maryland School of Medicine. Her work revolutionized the treatment of hormone-driven cancers, such as breast and prostate cancer, leading to improved outcomes for patients worldwide.

Collaborations: Throughout her career, Angela Brodie collaborated with leading pharmaceutical companies, research institutions, and fellow inventors to further advance cancer treatment options. Her collaborative efforts resulted in the development of innovative therapies that have saved countless lives.

Conclusion: Angela Brodie's pioneering work in cancer research has left an indelible mark on the field, shaping the way we approach hormone-related cancers. Her legacy continues to inspire future generations of inventors and researchers to push the boundaries of innovation in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.